Australia Approves Daily Oral Wegovy Tablet for Weight Management
New daily semaglutide tablets offer an alternative to weekly injections for weight loss.
1Regulatory Approval Granted
The Australian Therapeutic Goods Administration has officially registered the oral version of Wegovy for weight management. This marks the first time a daily GLP-1 tablet has been approved in the country. The medication, manufactured by Novo Nordisk, is available in four distinct strengths: 1.5mg, 4mg, 9mg, and 25mg.
2Mechanism of Action
Wegovy contains semaglutide, which mimics the GLP-1 hormone to regulate appetite and digestion. The drug acts on the brain and digestive system to increase feelings of fullness and slow stomach emptying. By reducing hunger, it assists adults living with obesity or weight-related health conditions in achieving sustainable weight loss.
3Tablet Versus Injection
Unlike weekly injections, the tablet must be taken daily on an empty stomach with water. Patients must wait 30 minutes before consuming other food or drinks to ensure proper absorption. Clinical trials indicate similar efficacy, with tablets showing 14% weight loss compared to 15% for injections over 64 to 68 weeks.
4Cardiovascular Health Benefits
Beyond weight management, the medication is approved to reduce the risk of serious cardiovascular events. Eligible adults may be prescribed the drug to lower the likelihood of heart attacks or strokes. It is intended to be used alongside a reduced-calorie diet, increased physical activity, and professional medical guidance.
5Potential Side Effects
Approximately 80% of patients experience gastrointestinal side effects, including nausea, vomiting, and constipation. More serious, though rarer, risks include pancreatitis, gallbladder issues, and kidney injury. Research has also noted potential links between GLP-1 use and suicidal thoughts, necessitating careful screening by healthcare professionals during short clinical appointments.
6Availability and Pricing
Novo Nordisk expects the tablets to be available in Australia by the end of the year. Currently, Wegovy is not subsidized through the Pharmaceutical Benefits Scheme for weight management. Patients should anticipate paying full out-of-pocket costs, which are expected to mirror the current monthly expense of A$250 to A$450.
7Subsidy Negotiations Ongoing
The federal government is negotiating with the manufacturer to potentially include Wegovy on the Pharmaceutical Benefits Scheme for specific patient cohorts. If successful, this could reduce costs to A$25 per script. Currently, about 400,000 Australians pay up to A$5,000 annually for GLP-1 medications, excluding those with Type 2 Diabetes.
8Future Clinical Outlook
Endocrinologists suggest that once prices decrease, these medications may be managed similarly to standard blood pressure or cholesterol treatments. While the tablet offers convenience for travelers and those avoiding needles, it is not a quick fix. Success relies on strict adherence to daily dosing and comprehensive lifestyle management strategies.